MGEA5 — O-GlcNAcase (OGA)

MGEA5 — O-GlcNAcase (OGA)

Gene Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MGEA5 — O-GlcNAcase (OGA)</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>MGEA5</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Meningioma Expressed Antigen 5 (N-acetylneuraminidase)</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>10q24.32</td>
</tr>
<tr>
<td class="label">Protein Product</td>
<td>O-GlcNAcase (OGA)</td>
</tr>
<tr>
<td class="label">EC Number</td>
<td>3.2.1.96</td>
</tr>
<tr>
<td class="label">Alternative Names</td>
<td>OGA, MGEA5, NCOAT (Nuclear Cytoplasmic O-GlcNAcase and Transcriptional coactivator)</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9H3K2</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>917 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~103 kDa</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">FNP-223 (Etiglutide)</td>
<td>Ferrer</td>
</tr>
<tr>
<td class="label">LY-3372689 (Zaniglusab)</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td class="label">MK-8719</td>
<td>Merck</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Biological Function

MGEA5 — O-GlcNAcase (OGA)

Gene Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MGEA5 — O-GlcNAcase (OGA)</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>MGEA5</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Meningioma Expressed Antigen 5 (N-acetylneuraminidase)</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>10q24.32</td>
</tr>
<tr>
<td class="label">Protein Product</td>
<td>O-GlcNAcase (OGA)</td>
</tr>
<tr>
<td class="label">EC Number</td>
<td>3.2.1.96</td>
</tr>
<tr>
<td class="label">Alternative Names</td>
<td>OGA, MGEA5, NCOAT (Nuclear Cytoplasmic O-GlcNAcase and Transcriptional coactivator)</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9H3K2</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>917 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~103 kDa</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">FNP-223 (Etiglutide)</td>
<td>Ferrer</td>
</tr>
<tr>
<td class="label">LY-3372689 (Zaniglusab)</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td class="label">MK-8719</td>
<td>Merck</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Biological Function

MGEA5 encodes O-GlcNAcase (OGA), a glycoside hydrolase that catalyzes the removal of O-linked β-N-acetylglucosamine (O-GlcNAc) from serine and threonine residues on target proteins. This enzyme is a key component of the O-GlcNAcylation cycle, a dynamic post-translational modification (PTM) that regulates numerous cellular processes:

Enzymatic Mechanism

OGA employs a substrate-assisted retention mechanism distinct from classical hydrolytic enzymes:

The catalytic center contains two essential aspartate residues (Asp174 and Asp175) that coordinate the substrate and facilitate catalysis[@ogacrystalstructure].

Domain Structure

MGEA5/OGA contains two functional domains:

• N-terminal Domain: Contains the catalytic machinery and binds O-GlcNAcylated substrates. The active site pocket is highly conserved across species.
• C-terminal Domain: May function in substrate recognition and protein-protein interactions. Contains several proline-rich regions.

Protein Structure and Catalysis

Crystal Structure

The three-dimensional structure of human OGA has been solved, revealing:

• A TIM-barrel fold in the catalytic domain
• A shallow substrate-binding groove
• Two critical catalytic aspartates in the active site
• Conformational flexibility that may allow accommodation of diverse substrates[@ogacrystalstructure]

Substrate Specificity

OGA demonstrates:

• High specificity for O-GlcNAc over other glycosidic linkages
• Competitive inhibition by NAG-thiazoline compounds
• pH optimum around pH 5.5-6.0 in vitro
• Activity on both nuclear and cytoplasmic proteins

Expression Patterns in the Brain

Cellular Distribution

OGA is expressed throughout the brain with distinct patterns:

• Neurons: Highest expression in cortical pyramidal neurons, hippocampal CA1-CA3 neurons, and Purkinje cells in the cerebellum.
• Astrocytes: Moderate expression, particularly in white matter tracts.
• Microglia: Expression increases upon activation.
• Oligodendrocytes: Lower baseline expression, increases during myelination.

Regional Distribution

OGA activity is highest in:

• Cerebral cortex (particularly frontal and temporal lobes)
• Hippocampus (CA1 region most vulnerable in AD)
• Basal ganglia
• Brainstem motor nuclei

Disease-Associated Changes

In neurodegenerative diseases, OGA expression is altered:

• Alzheimer's disease: Reduced OGA activity in the hippocampus and cortex[@ogasexpression], correlating with tau pathology severity.
• Parkinson's disease: Variable changes in OGA levels in the substantia nigra and striatum[@ogainpd].
• Progressive supranuclear palsy: Increased OGA in affected brain regions, potentially as a compensatory response.

Role in Alzheimer's Disease

Tau O-GlcNAcylation

OGA regulates the O-GlcNAcylation of tau protein at multiple sites:

• Competition with phosphorylation: O-GlcNAcylation and phosphorylation compete for the same serine/threonine residues (Thr231, Ser396, Ser404).
• Protection against aggregation: O-GlcNAcylated tau shows reduced fibrillization in vitro.
• NFT correlation: Tau in neurofibrillary tangles has reduced O-GlcNAcylation compared to soluble tau[@ogatauphosphorylation].

Amyloid Interplay

OGA influences amyloid pathology through:

• APP processing: O-GlcNAcylation of APP at Thr576 reduces β-secretase cleavage.
• BACE1 modulation: O-GlcNAcylation of BACE1 decreases its activity.
• Amyloid-beta effects: Aβ exposure reduces global O-GlcNAcylation, creating a feed-forward cycle.

Synaptic Function

OGA inhibition improves synaptic plasticity and memory:

• Enhanced long-term potentiation (LTP) in hippocampal slices[@ogamemory]
• Improved performance on spatial memory tasks in mice
• Protection against excitotoxic neuronal death

Therapeutic Implications

Increasing tau O-GlcNAcylation through OGA inhibition represents a promising AD therapeutic strategy that:

• Directly targets tau pathology
• Complements amyloid-targeting approaches
• May protect synaptic function

Role in Parkinson's Disease

Alpha-Synuclein O-GlcNAcylation

OGA modulates α-synuclein pathology:

• O-GlcNAcylation of α-synuclein at Ser87 reduces aggregation propensity.
• O-GlcNAcylated α-synuclein shows altered membrane binding.
• Reduced aggregation correlates with decreased toxicity in cell models[@ogasynuclein].

Dopaminergic Neurons

OGA function is particularly relevant to dopaminergic neuron survival:

• Metabolic stress reduces O-GlcNAcylation in these neurons.
• OGA inhibition protects against MPTP-induced toxicity.
• May modulate LRRK2 kinase activity through O-GlcNAcylation.

Neuroinflammation

Microglial OGA regulates inflammatory responses:

• O-GlcNAcylation of IκB kinase (IKK) modulates NF-κB signaling.
• OGA inhibition reduces pro-inflammatory cytokine production.
• Potential for modulating neuroinflammation in PD[@ogamicroglia].

Role in Tauopathies (PSP, CBS)

PSP-Specific Effects

Progressive supranuclear palsy shows particular sensitivity to OGA modulation:

• Elevated tau phosphorylation at multiple epitopes
• OGA inhibition reduces pathological phosphorylation
• Neurofibrillary tangles contain under-O-GlcNAcylated tau

CBS (Corticobasal Syndrome)

OGA targeting may benefit CBS through:

• Tau pathology modification in cortical neurons
• Protection of GABAergic interneurons
• Modulation of astrocyte reactivity

Clinical Trials

Several OGA inhibitors have entered clinical development:

Interaction Partners

Enzymatic Partners

• OGT (O-GlcNAc transferase): The counter-enzyme that adds O-GlcNAc. OGA and OGT function in a dynamic cycle.
• NAG (N-acetylglucosaminidase): Involved in the salvage pathway of GlcNAc.

Protein Substrates

Key neurodegeneration-relevant substrates:

• Tau: Multiple sites including Thr231, Ser396, Ser404
• α-Synuclein: Ser87, Thr72, Tyr133
• APP: Thr576
• BACE1: Multiple sites
• Synapsin I: Synaptic vesicle regulation
• MAPK kinases: Signaling pathway modulation

Regulatory Proteins

• P38 MAPK: Phosphorylation regulates OGA activity
• PP1/PP2A: Phosphatases that may dephosphorylate OGA
• 14-3-3 proteins: Bind and regulate OGA localization

Metabolic Regulation

Glucose Metabolism Link

OGA activity is linked to cellular metabolism:

• UDP-GlcNAc availability depends on glucose flux through the hexosamine biosynthesis pathway
• Nutrient status directly affects O-GlcNAcylation levels
• Diabetes risk variants in MGEA5 may alter this relationship[@ogametabolism]

Mitochondrial Function

OGA regulates mitochondrial proteins:

• O-GlcNAcylation of respiratory chain complexes
• Modulation of ATP production
• Protection against oxidative stress[@ogamitochondria]

Therapeutic Targeting

OGA Inhibitors in Development

FNP-223 (Etiglutide)

• Mechanism: Thiazoline-based OGA inhibitor
• Delivery: Oral administration
• Phase: Phase 2 for PSP
• Results: Reduced CSF tau in dose-escalation study

LY-3372689 (Zaniglusab)

• Mechanism: NAG-thiazoline analog
• Delivery: Intravenous infusion
• Phase: Phase 2 for AD and PSP
• Rationale: Enhanced brain penetration

MK-8719

• Mechanism: Selective OGA inhibitor
• Delivery: Oral
• Phase: Phase 1 completed
• Status: No further development announced

Mechanism of Action

OGA inhibition increases O-GlcNAcylation of tau and other proteins, which:

• Reduces phosphorylation at disease-relevant epitopes (Thr231, Ser396, Ser404)
• Decreases tau aggregation and NFT formation
• May protect against neuronal death
• Modulates synaptic protein function

Challenges and Considerations

• Blood-brain barrier penetration: Critical for CNS efficacy
• Peripheral activity: May cause gastrointestinal side effects
• Long-term safety: Chronic OGA inhibition effects unknown
• Biomarker development: Need to monitor target engagement[@ogabiomarker]

Animal Models

Knockout Mice

• MGEA5 knockout: Embryonic lethal, demonstrating essential function
• Conditional knockout: Brain-specific deletion causes neurodegeneration
• Phenotype: Impaired O-GlcNAcylation, tau hyperphosphorylation

Transgenic Models

• hTau mice: OGA inhibition reduces tau pathology
• APP/PS1 mice: OGA inhibition improves memory
• α-synuclein models: Reduced aggregation with OGA inhibition

Biomarkers for OGA-Targeted Therapy

CSF Biomarkers

• Total tau: Decreases with effective OGA inhibition
• Phospho-tau: Reduced at target epitopes
• O-GlcNAcylated proteins: Potential direct biomarker[@ogabiomarker]

Blood-Based Biomarkers

• Peripheral blood mononuclear cell O-GlcNAcylation: May correlate with CNS target engagement
• Platelet OGA activity: Potential pharmacodynamic marker

Imaging Biomarkers

• PET tau ligands: May track treatment effects
• FDG-PET: Metabolic changes with treatment

Genetic Variants

Common Variants

• SNPs in MGEA5 associated with type 2 diabetes risk
• May influence OGA expression levels
• No direct link to neurodegeneration risk

Rare Variants

• No known pathogenic mutations causing neurodegeneration
• Gene is considered essential

Research Directions

Emerging Areas

Key Questions

• What is the optimal level of OGA inhibition?
• Which patient populations will benefit most?
• Can OGA inhibition modify disease progression?
• What are long-term safety implications?

Cross-Links

• [OGA Inhibitor Landscape](/therapeutics/oga-inhibitor-landscape) — Clinical programs and competitive landscape
• [O-GlcNAcylation Pathway](/mechanisms/protein-o-glcna-cylation-pathway) — Detailed mechanism of O-GlcNAc modification
• [Tau Phosphorylation](/mechanisms/tau-phosphorylation-kinases) — Phosphorylation as competing PTM
• [Tau-Targeted Therapeutics](/therapeutics/tau-targeted-therapeutics) — Other tau-modulating approaches
• [PSP Treatment Plan](/therapeutics/personalized-treatment-plan-atypical-parkinsonism) — Clinical context
• [Alpha-Synuclein](/proteins/alpha-synuclein) — O-GlcNAcylation effects on synucleinopathy

References